• 1. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

Professional Introduction to 4-Chloro-6-isopropyl-2-(pyridin-2-YL)pyrimidine (CAS No. 1153412-93-1)

4-Chloro-6-isopropyl-2-(pyridin-2-YL)pyrimidine, identified by its CAS number 1153412-93-1, is a significant compound in the field of pharmaceutical chemistry. This pyrimidine derivative has garnered considerable attention due to its versatile applications in the development of novel therapeutic agents. The compound’s unique structural features, including a chloro substituent at the 4-position and an isopropyl group at the 6-position, combined with a pyridin-2-yl moiety, make it a valuable scaffold for medicinal chemists.

The chemical structure of 4-Chloro-6-isopropyl-2-(pyridin-2-YL)pyrimidine contributes to its reactivity and potential biological activity. The presence of the chloro group enhances its utility in various synthetic transformations, allowing for further functionalization. Additionally, the isopropyl group introduces steric hindrance, which can influence the compound’s binding affinity and selectivity in biological targets. The pyridin-2-yl moiety, on the other hand, is known to improve solubility and metabolic stability, making it an attractive feature for drug development.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors targeting various disease pathways. Pyrimidine derivatives have emerged as a prominent class of compounds due to their ability to interact with biological macromolecules such as enzymes and receptors. 4-Chloro-6-isopropyl-2-(pyridin-2-YL)pyrimidine has been explored in several preclinical studies as a potential lead compound for treating conditions such as cancer and inflammatory diseases.

One of the most compelling aspects of this compound is its role in kinase inhibition. Kinases are enzymes that play a crucial role in cell signaling pathways and are often dysregulated in diseases like cancer. Researchers have leveraged the structural features of 4-Chloro-6-isopropyl-2-(pyridin-2-YL)pyrimidine to design inhibitors that specifically target aberrant kinases involved in tumor growth and progression. Preliminary studies have shown promising results in vitro, demonstrating potent inhibition of several kinases with high selectivity.

The synthesis of 4-Chloro-6-isopropyl-2-(pyridin-2-YL)pyrimidine involves multi-step organic reactions that require careful optimization to ensure high yield and purity. The chlorination step at the 4-position is particularly critical, as it determines the reactivity of the compound in subsequent synthetic steps. Advanced techniques such as palladium-catalyzed cross-coupling reactions have been employed to introduce the pyridin-2-yl moiety efficiently.

The pharmacokinetic properties of 4-Chloro-6-isopropyl-2-(pyridin-2-YL)pyrimidine have also been extensively studied. These studies aim to understand how the compound is absorbed, distributed, metabolized, and excreted by the body. The presence of the isopropyl group has been found to enhance oral bioavailability, while the pyridin-2-yl moiety contributes to metabolic stability. These findings are crucial for optimizing drug formulations and ensuring therapeutic efficacy.

In conclusion, 4-Chloro-6-isopropyl-2-(pyridin-2-YL)pyrimidine (CAS No. 1153412-93-1) represents a promising candidate for further development in pharmaceutical research. Its unique structural features and demonstrated biological activity make it a valuable tool for medicinal chemists seeking to develop novel therapeutics. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in addressing unmet medical needs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)